‘GLP-1s for Everything!’: Balancing Access With Sustainability

Glucagon-like peptide-1 receptor agonists are moving far beyond their established uses for managing type 2 diabetes and weight loss, posing potential new challenges for payors, according to a presentation at the AMCP 2025 meeting.